Skip to content

A clinical trial to study the effect of a drug,Taurine in Subjects having traumatic Spinal cord INJURY

Role of Taurine Supplementation in Neurological Recovery of Acute Spinal Cord Injury (ASCI) Subjects: A Non Randomized Control Clinical Trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047262
Enrollment
53
Registered
2022-11-14
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G89-G99- Other disorders of the nervous system Health Condition 2: G89-G99- Other disorders of the nervous system

Interventions

Intervention1: Taurine: 3 grams of taurine supplementation orally per day in three divided doses (1000 mg) for six months. Intervention2: Taurine: 3 grams of taurine supplementation orally per day in

Sponsors

King georges medical university,Department of Orhopaedic Surgery
Lead Sponsor
Department of biochemistry
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria for controls Age and sex matched healthy controls were amongst the attendants of the ASCI subjects, having no known pathology and gave their consent to participate in the study. Inclusion criterion for ASCI subjects 1. Age 18 - 65 years of either gender, 2. ASCI 3. Complete motor injury (AIS-A, B)

Exclusion criteria

Exclusion criteria: Exclusion criterion for ASCI subjects 1. Other associated injuries such as major thoracoabdominal injuries & head injuries needing intervention. 2. Neuro-psychiatric patients and patients on steroid or other immunosuppressant therapy or other comorbid conditions making subjects unfit for surgery. 3. Subjects with non-vegetarian diet. 4. Subjects who do not give consent for participating in the study.

Design outcomes

Primary

MeasureTime frame
Taurine supplementation improves; AIS Scale, Sensory- Motor and SCIM and SF-36scores following in ASCI subjects.Taurine supplementation promotes Neurological Recovery.Timepoint: During Admission,3rd Week,3rd month,6th Month.

Secondary

MeasureTime frame
Taurine supplementation improves; AIS Scale, Sensory- Motor and SCIM and SF-36 scores following in ASCI subjects, other none targeted metabolites which are exceeding that variable importance on projection (VIP) scores greater than taurine then they will also be considered in this study.Timepoint: 8 month,12 month,24 month.

Countries

India

Contacts

Public ContactZeenat Ara

KGMU

drrnsrivastava@yahoo.com09792229688

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026